CCL2

From Wikipedia, the free encyclopedia
Jump to: navigation, search

For the ICAO airport code see Candle Lake Airpark, for the diradical compound see Dichlorocarbene.

Chemokine (C-C motif) ligand 2
Protein CCL2 PDB 1dok.png
PDB rendering based on 1dok.
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols CCL2 ; GDCF-2; HC11; HSMCR30; MCAF; MCP-1; MCP1; SCYA2; SMC-CF
External IDs OMIM158105 MGI98259 HomoloGene2245 ChEMBL: 1649052 GeneCards: CCL2 Gene
RNA expression pattern
PBB GE CCL2 216598 s at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez 6347 20293
Ensembl ENSG00000108691 ENSMUSG00000035352
UniProt P13500 Q62401
RefSeq (mRNA) NM_002982 NM_011331
RefSeq (protein) NP_002973 NP_035461
Location (UCSC) Chr 17:
32.58 – 32.58 Mb
Chr 11:
82.1 – 82.1 Mb
PubMed search [1] [2]

The chemokine (C-C motif) ligand 2 (CCL2) is also referred to as monocyte chemotactic protein 1 (MCP1) and small inducible cytokine A2. CCL2 is a small cytokine that belongs to the CC chemokine family. CCL2 recruits monocytes, memory T cells, and dendritic cells to the sites of inflammation produced by either tissue injury or infection.[1][2]

Genomics[edit]

In the human genome, CCL2 and many other CC chemokines are located on chromosome 17 (17q11.2-q21.1).[3] The gene span is 1,927 bases and the CCL2 gene resides on the Watson (plus) strand. The CCL2 gene has three exons and two introns. The CCL2 protein precursor contains a signal peptide of 23 amino acids. In turn, the mature CCL2 is 76 amino acids long.[4][5] The CCL2 predicted weight is 11.025 kiloDaltons (kDa).

The gene homologous to CCL2 in the mouse is Sig-je.

Population genetics[edit]

In humans, the levels of CCL2 can vary considerably. In the white people of European descent, the multivariable-adjusted heritability of CCL2 concentrations is as much as 0.37 in the blood plasma and 0.44 - in the serum[6][7]

Molecular biology[edit]

CCL2 is a monomeric polypeptide, with a molecular weight of approximately 13 kDa. CCL2 is anchored in the plasma membrane of endothelial cells by glycosaminoglycan side chains of proteoglycans. CCL2 is primarily secreted by monocytes, macrophages and dendritic cells. Platelet derived growth factor is a major inducer of CCL2 gene. To become activated CCL2 protein has to be cleaved by metalloproteinase MMP-12.

CCR2 and CCR4 are two cell surface receptors that bind CCL2.[8]

CCL2 exhibits a chemotactic activity for monocytes and basophils. However, it does not attract neutrophils or eosinophils. After deletion of the N-terminal residue, CCL2 loses its attractivity for basophils and becomes a chemoattractant of eosinophils. Basophils and mast cells that are treated with CCL2 releases their granules to the intercellular space. This effect can be also potentiated by a pre-treatment with IL-3 or even by other cytokines.[9][10] CCL2 augments monocyte anti-tumor activity and it is essential for formation of granulomas.

CCL2 can be found at the sites of tooth eruption and bone degradation. In the bone, CCL2 is expressed by mature osteoclasts and osteoblasts and it is under control of nuclear factor κB (NFκB). In the human osteoclasts, CCL2 and RANTES (regulated on activation normal T cell expressed and secreted). Both MCP-1 and RANTES induce formation of TRAP-positive, multinuclear cells from M-CSF-treated monocytes in the absence of RANKL, but produced osteoclasts that lacked cathepsin K expression and resorptive capacity. It is proposed that CCL2 and RANTES act as autocrine loop in human osteoclast differentiation.[11]

The CCL2 chemokine is also expressed by neurons, astrocytes and microglia. The expression of CCL2 in neurons is mainly found in the cerebral cortex, globus pallidus, hippocampus, paraventricular and supraoptic hypothalamic nuclei, lateral hypothalamus, substantia nigra, facial nuclei, motor and spinal trigeminal nuclei, gigantocellular reticular nucleus and in Purkinje cells in the cerebellum.[12]

Clinical importance[edit]

CCL2 is implicated in pathogeneses of several diseases characterized by monocytic infiltrates, such as psoriasis, rheumatoid arthritis and atherosclerosis.[13]

Administration of anti-CCL2 antibodies in a model of glomerulonephritis reduces infiltration of macrophages and T cells, reduces crescent formation, as well as scarring and renal impairment.[14]

CCL2 is involved in the neuroinflammatory processes that takes place in the various diseases of the central nervous system (CNS), which are characterized by neuronal degeneration.[15] CCL2 expression in glial cells is increased in epilepsy,[16][17] brain ischemia[18] Alzheimer’s disease[19] experimental autoimmune encephalomyelitis (EAE),[20] and traumatic brain injury.[21]

Hypomethylation of CpG sites within the CCL2 promoter region is affected by high levels of blood glucose and TG, which increase CCL2 levels in the blood serum. The later plays an important role in the vascular complications of type 2 diabetes[22]

CCL2 induces amylin expression through ERK1/ERK2/JNK-AP1 and NF-κB related signaling pathways independent of CCR2. Amylin upregulation by CCL2 contributes to the elevation of the plasma amylin and insulin resistance in obesity.[23]

Adipocytes secrete various adipokines that may be involved in the negative cross-talk between adipose tissue and skeletal muscle. CCL2 impairs insulin signaling in skeletal muscle cells via ERK1/2 activation at doses similar to its physiological plasma concentrations (200 pg/mL), but does not involve activation of the NF-κB pathway. CCL2 significantly reduced insulin-stimulated glucose uptake in myocytes. CCL2 may represent a molecular link in the negative cross-talk between adipose tissue and skeletal muscle assigning a completely novel important role to CCL2 besides inflammation.[24]

Incubation of HL-1 cardiomyocytes and human myocytes with oxidized-LDL induced the expression of BNP and CCL2 genes, while native LDL (N-LDL) had no effect.[25]

Treatment with melatonin in old mice with age related liver inflammation decreased the mRNA expression of TNF-α, IL-1β, HO (HO-1 and HO-2), iNOS, CCL2, NF-κB1, NF-κB2 and NKAP in old male mice. The protein expression of TNF-α, IL-1β was also decreased and IL-10 increased with melatonin treatment. Exogenous administration of melatonin was able to reduce inflammation.[26]

References[edit]

  1. ^ Carr, M. W.; Roth, S. J.; Luther, E.; Rose, S. S.; Springer, T. A. (1994). "Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant". Proceedings of the National Academy of Sciences of the United States of America 91 (9): 3652–3656. doi:10.1073/pnas.91.9.3652. PMC 43639. PMID 8170963.  edit
  2. ^ Xu, L. L.; Warren, M. K.; Rose, W. L.; Gong, W.; Wang, J. M. (1996). "Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro". Journal of leukocyte biology 60 (3): 365–371. PMID 8830793.  edit
  3. ^ Mehrabian, M.; Sparkes, R. S.; Mohandas, T.; Fogelman, A. M.; Lusis, A. J. (1991). "Localization of monocyte chemotactic protein-1 gene (SCYA2) to human chromosome 17q11.2-q21.1". Genomics 9 (1): 200–203. doi:10.1016/0888-7543(91)90239-B. PMID 2004761.  edit
  4. ^ Yoshimura, T.; Yuhki, N.; Moore, S. K.; Appella, E.; Lerman, M. I.; Leonard, E. J. (1989). "Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE". FEBS Letters 244 (2): 487–493. doi:10.1016/0014-5793(89)80590-3. PMID 2465924.  edit
  5. ^ Furutani, Y.; Nomura, H.; Notake, M.; Oyamada, Y.; Fukui, T.; Yamada, M.; Larsen, C. G.; Oppenheim, J. J.; Matsushima, K. (1989). "Cloning and sequencing of the cDNA for human monocyte chemotactic and activating factor (MCAF)". Biochemical and Biophysical Research Communications 159 (1): 249–255. doi:10.1016/0006-291X(89)92430-3. PMID 2923622.  edit
  6. ^ McDermott, D. H.; Yang, Q.; Kathiresan, S.; Cupples, L. A.; Massaro, J. M.; Keaney Jr, J. F.; Larson, M. G.; Vasan, R. S.; Hirschhorn, J. N.; O'Donnell, C. J.; Murphy, P. M.; Benjamin, E. J. (2005). "CCL2 Polymorphisms Are Associated with Serum Monocyte Chemoattractant Protein-1 Levels and Myocardial Infarction in the Framingham Heart Study". Circulation 112 (8): 1113–1120. doi:10.1161/CIRCULATIONAHA.105.543579. PMID 16116069.  edit
  7. ^ Bielinski, S. J.; Pankow, J. S.; Miller, M. B.; Hopkins, P. N.; Eckfeldt, J. H.; Hixson, J.; Liu, Y.; Register, T.; Myers, R. H.; Arnett, D. K. (2007). "Circulating MCP-1 levels shows linkage to chemokine receptor gene cluster on chromosome 3: The NHLBI Family Heart Study follow-up examination". Genes and Immunity 8 (8): 684–690. doi:10.1038/sj.gene.6364434. PMID 17917677.  edit
  8. ^ Craig, M. J.; Loberg, R. D. (2006). "CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases". Cancer and Metastasis Reviews 25 (4): 611–619. doi:10.1007/s10555-006-9027-x. PMID 17160712.  edit
  9. ^ Conti, P.; Boucher, W.; Letourneau, R.; Feliciani, C.; Reale, M.; Barbacane, R. C.; Vlagopoulos, P.; Bruneau, G.; Thibault, J.; Theoharides, T. C. (1995). "Monocyte chemotactic protein-1 provokes mast cell aggregation and 3H5HT release". Immunology 86 (3): 434–440. PMC 1383948. PMID 8550082.  edit
  10. ^ Bischoff, S. C.; Krieger, M.; Brunner, T.; Dahinden, C. A. (1992). "Monocyte chemotactic protein 1 is a potent activator of human basophils". The Journal of experimental medicine 175 (5): 1271–1275. doi:10.1084/jem.175.5.1271. PMC 2119199. PMID 1569397.  edit
  11. ^ Kim, M. S.; Day, C. J.; Morrison, N. A. (2005). "MCP-1 is Induced by Receptor Activator of Nuclear Factor- B Ligand, Promotes Human Osteoclast Fusion, and Rescues Granulocyte Macrophage Colony-stimulating Factor Suppression of Osteoclast Formation". Journal of Biological Chemistry 280 (16): 16163–16169. doi:10.1074/jbc.M412713200. PMID 15722361.  edit
  12. ^ Banisadr, G.; Gosselin, R. D.; Mechighel, P.; Kitabgi, P.; Rostène, W.; Parsadaniantz, S. P. M. L. (2005). "Highly regionalized neuronal expression of monocyte chemoattractant protein-1 (MCP-1/CCL2) in rat brain: Evidence for its colocalization with neurotransmitters and neuropeptides". The Journal of Comparative Neurology 489 (3): 275–292. doi:10.1002/cne.20598. PMID 16025454.  edit
  13. ^ Xia, M.; Sui, Z. (2009). "Recent developments in CCR2 antagonists". Expert Opinion on Therapeutic Patents 19 (3): 295–303. doi:10.1517/13543770902755129. PMID 19441905.  edit
  14. ^ Lloyd, C. M.; Minto, A. W.; Dorf, M. E.; Proudfoot, A.; Wells, T. N.; Salant, D. J.; Gutierrez-Ramos, J. C. (1997). "RANTES and Monocyte Chemoattractant Protein–1 (MCP-1) Play an Important Role in the Inflammatory Phase of Crescentic Nephritis, but Only MCP-1 is Involved in Crescent Formation and Interstitial Fibrosis". The Journal of experimental medicine 185 (7): 1371–1380. doi:10.1084/jem.185.7.1371. PMC 2196251. PMID 9104823.  edit
  15. ^ Gerard, C.; Rollins, B. J. (2001). "Chemokines and disease". Nature Immunology 2 (2): 108–115. doi:10.1038/84209. PMID 11175802.  edit
  16. ^ Foresti, M. L.; Arisi, G. M.; Katki, K.; Montañez, A.; Sanchez, R. M.; Shapiro, L. A. (2009). "Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced status epilepticus". Journal of Neuroinflammation 6: 40. doi:10.1186/1742-2094-6-40. PMC 2804573. PMID 20034406.  edit
  17. ^ Fabene, P. F.; Bramanti, P.; Constantin, G. (2010). "The emerging role for chemokines in epilepsy". Journal of Neuroimmunology 224 (1–2): 22–27. doi:10.1016/j.jneuroim.2010.05.016. PMID 20542576.  edit
  18. ^ Kim, J. S.; Gautam, S. C.; Chopp, M.; Zaloga, C.; Jones, M. L.; Ward, P. A.; Welch, K. M. (1995). "Expression of monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 after focal cerebral ischemia in the rat". Journal of neuroimmunology 56 (2): 127–134. PMID 7860708.  edit
  19. ^ Hickman, S. E.; El Khoury, J. (2010). "Mechanisms of mononuclear phagocyte recruitment in Alzheimer's disease". CNS & neurological disorders drug targets 9 (2): 168–173. doi:10.2174/187152710791011982. PMID 20205643.  edit
  20. ^ Ransohoff, R. M.; Hamilton, T. A.; Tani, M.; Stoler, M. H.; Shick, H. E.; Major, J. A.; Estes, M. L.; Thomas, D. M.; Tuohy, V. K. (1993). "Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis". The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 7 (6): 592–600. PMID 8472896.  edit
  21. ^ Semple, B. D.; Bye, N.; Rancan, M.; Ziebell, J. M.; Morganti-Kossmann, M. C. (2009). "Role of CCL2 (MCP-1) in traumatic brain injury (TBI): Evidence from severe TBI patients and CCL2−/− mice". Journal of Cerebral Blood Flow & Metabolism 30 (4): 769–782. doi:10.1038/jcbfm.2009.262. PMC 2949175. PMID 20029451.  edit
  22. ^ Liu, Z. H.; Chen, L. L.; Deng, X. L.; Song, H. J.; Liao, Y. F.; Zeng, T. S.; Zheng, J.; Li, H. Q. (2011). "Methylation Status of CpG Sites in the MCP-1 Promoter is Correlated to Serum MCP-1 in type 2 Diabetes". Journal of endocrinological investigation. doi:10.3275/7981. PMID 21975431.  edit
  23. ^ Cai, K.; Qi, D.; Hou, X.; Wang, O.; Chen, J.; Deng, B.; Qian, L.; Liu, X.; Le, Y. (2011). Fadini, Gian Paolo, ed. "MCP-1 Upregulates Amylin Expression in Murine Pancreatic β Cells through ERK/JNK-AP1 and NF-κB Related Signaling Pathways Independent of CCR2". PLoS ONE 6 (5): e19559. doi:10.1371/journal.pone.0019559. PMC 3092759. PMID 21589925.  edit
  24. ^ Sell, H.; Dietze-Schroeder, D.; Kaiser, U.; Eckel, J. (2006). "Monocyte Chemotactic Protein-1 is a Potential Player in the Negative Cross-Talk between Adipose Tissue and Skeletal Muscle". Endocrinology 147 (5): 2458–2467. doi:10.1210/en.2005-0969. PMID 16439461.  edit
  25. ^ Chandrakala, A. N.; Sukul, D.; Selvarajan, K.; Sai-Sudhakar, C.; Sun, B.; Parthasarathy, S. (2011). "Induction of Brain Natriuretic Peptide and Monocyte Chemotactic Protein1 Gene Expressions by Oxidized Lowdensity Lipoprotein-Relevance to Ischemic Heart Failure". AJP: Cell Physiology 302 (1): C165–77. doi:10.1152/ajpcell.00116.2011. PMID 21900689.  edit
  26. ^ Cuesta, S.; Kireev, R.; Forman, K.; García, C.; Escames, G.; Ariznavarreta, C.; Vara, E.; Tresguerres, J. S. A. F. (2010). "Melatonin improves inflammation processes in liver of senescence-accelerated prone male mice (SAMP8)". Experimental Gerontology 45 (12): 950–956. doi:10.1016/j.exger.2010.08.016. PMID 20817086.  edit

Further reading[edit]

  • Yoshimura, T.; Leonard, E. J. (1991). "Human monocyte chemoattractant protein-1 (MCP-1)". Advances in experimental medicine and biology 305: 47–56. doi:10.1007/978-1-4684-6009-4_6. PMID 1661560.  edit
  • Wahl, S. M.; Greenwell-Wild, T.; Hale-Donze, H.; Moutsopoulos, N.; Orenstein, J. M. (2000). "Permissive factors for HIV-1 infection of macrophages". Journal of leukocyte biology 68 (3): 303–310. PMID 10985244.  edit
  • Sell, H.; Eckel, J. R. (2007). "Monocyte chemotactic protein-1 and its role in insulin resistance". Current Opinion in Lipidology 18 (3): 258–262. doi:10.1097/MOL.0b013e3281338546. PMID 17495598.  edit